Renaissance Technologies LLC Trims Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Renaissance Technologies LLC reduced its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 12.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,025,868 shares of the specialty pharmaceutical company’s stock after selling 139,700 shares during the quarter. Renaissance Technologies LLC owned 1.63% of Jazz Pharmaceuticals worth $109,491,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Rise Advisors LLC grew its stake in Jazz Pharmaceuticals by 2,255.6% in the 1st quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company’s stock worth $26,000 after acquiring an additional 203 shares in the last quarter. Versant Capital Management Inc grew its stake in Jazz Pharmaceuticals by 13,450.0% in the 2nd quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock worth $29,000 after acquiring an additional 269 shares in the last quarter. GAMMA Investing LLC grew its stake in Jazz Pharmaceuticals by 65.5% in the 2nd quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock worth $31,000 after acquiring an additional 116 shares in the last quarter. Cape Investment Advisory Inc. grew its stake in Jazz Pharmaceuticals by 14,600.0% in the 4th quarter. Cape Investment Advisory Inc. now owns 294 shares of the specialty pharmaceutical company’s stock worth $36,000 after acquiring an additional 292 shares in the last quarter. Finally, Gladius Capital Management LP bought a new position in Jazz Pharmaceuticals in the 2nd quarter worth about $33,000. 89.14% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Jazz Pharmaceuticals

In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of Jazz Pharmaceuticals stock in a transaction on Friday, September 6th. The shares were sold at an average price of $108.30, for a total transaction of $152,703.00. Following the completion of the sale, the senior vice president now directly owns 14,531 shares in the company, valued at $1,573,707.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Price Performance

NASDAQ JAZZ opened at $109.57 on Tuesday. The firm’s fifty day simple moving average is $110.21 and its two-hundred day simple moving average is $111.20. The company has a current ratio of 2.37, a quick ratio of 2.02 and a debt-to-equity ratio of 1.36. Jazz Pharmaceuticals plc has a 12-month low of $99.06 and a 12-month high of $137.38. The firm has a market capitalization of $6.91 billion, a P/E ratio of 22.59, a P/E/G ratio of 1.31 and a beta of 0.57.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.80 by $0.87. Jazz Pharmaceuticals had a net margin of 10.10% and a return on equity of 28.65%. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1 billion. Analysts forecast that Jazz Pharmaceuticals plc will post 16.03 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have commented on JAZZ shares. Robert W. Baird dropped their target price on shares of Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating on the stock in a research note on Thursday, August 1st. HC Wainwright reissued a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, August 1st. Needham & Company LLC reissued a “buy” rating and set a $205.00 price objective on shares of Jazz Pharmaceuticals in a report on Tuesday, September 10th. Cantor Fitzgerald reissued an “overweight” rating and set a $140.00 price objective on shares of Jazz Pharmaceuticals in a report on Monday, September 9th. Finally, The Goldman Sachs Group began coverage on shares of Jazz Pharmaceuticals in a report on Wednesday, June 5th. They set a “buy” rating and a $169.00 price objective on the stock. Four analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $173.07.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.